Medication Access and Drug Shortages: How Providers Can Navigate Treatment Disruptions

The treatment plan is working. Then the patient calls: the pharmacy cannot fill the next prescription.

For providers, that call begins a second clinical assessment. How much medication remains? What would an interruption mean for this patient? Is another product available, or does treatment need to change?

Drug shortages can turn a routine refill into a time-sensitive decision. A clear response starts with identifying the access problem, then brings the prescriber, pharmacist, and patient together around a workable plan.

Drug Shortages: Verify the Scope of the Disruption

“Unavailable” can mean several things. A pharmacy may be out of stock, a manufacturer may have a product on backorder, or a broader shortage may affect several suppliers.

Start with the exact prescription: active ingredient, strength, dosage form, manufacturer when relevant, and dosing schedule. Ask the dispensing pharmacy what it can obtain and whether it has a credible estimate for replenishment.

Check FDA and American Society of Health-System Pharmacists, or ASHP, shortage resources. Their listings serve different purposes and may describe availability differently. A local backorder does not automatically establish FDA-listed shortage status.

Record when the information was checked. Supply conditions can change before the next refill.

Medication Access: Identify What Is Preventing Treatment

An available medication may still be inaccessible to the patient.

Ask whether the barrier is stock, insurance coverage, prior authorization, cost, transportation, or difficulty using the dosage form. Each calls for a different response. Finding another supplier will not resolve an unaffordable copayment, and changing therapy may create a new coverage problem.

Assess urgency at the same time. Confirm how much medication remains and the clinical consequences of a gap, rather than assuming every interruption carries the same risk.

Assign someone to close the loop with the patient. An alternative prescription is only useful if the patient can actually obtain it.

Therapeutic Alternatives: Evaluate the Full Prescription

An alternative may be another available product containing the same ingredient, a different strength or dosage form, or a different medication. These possibilities require different levels of review.

Do not assume equivalence.

Consider the indication, delivery characteristics, administration instructions, interactions, and monitoring needs. A route change may alter the balance of benefits and risks. A concentration change may require a different measured volume.

Confirm whether the pharmacist can make an appropriate substitution under applicable requirements or whether prescriber authorization is needed. Check availability and coverage before finalizing the plan.

The patient should receive one clear set of instructions. If the replacement looks different or follows a different schedule, explain those changes explicitly.

Estradiol Patches: A Recent Example of Uneven Availability

Estradiol patches illustrate why product-level details matter.

In its September 3, 2026 update, FDA acknowledged that increased demand had made some patients’ usual estradiol patches difficult to obtain. It also emphasized that patches remained available overall, with access varying by product and location. ASHP’s bulletin identifies affected products alongside available options.

For a patient unable to refill a usual patch, the first step is to check the exact product and ask whether another appropriate FDA-approved patch can be obtained.

If a different formulation is being considered, the prescriber should reassess the treatment rather than treat it as a simple refill substitution. An oral product or gel is not automatically a dose-for-dose replacement for a patch, and application schedules may differ between patch products.

Compounding During Drug Shortages: Understand the Conditions

Compounding may be an option in certain circumstances, but a shortage report does not answer every regulatory or clinical question.

FDA recommends prescribing an FDA-approved drug when available and appropriate. When a drug is on FDA’s shortage list, certain restrictions on compounding essentially copies may not apply; other requirements remain. For section 503A compounding, these include a valid prescription for an individual patient.

A local stock problem or an ASHP listing alone does not establish the FDA shortage-list exception. The pharmacy must evaluate the applicable requirements and whether it can prepare the medication.

Feasibility matters. Some products require processes or equipment a pharmacy does not have. A compounded cream also should not be assumed equivalent to an approved transdermal patch.

Discuss the unmet need, proposed preparation, and follow-up before prescribing. Compounded medications are not FDA-approved.

Pharmacist–Provider Collaboration: Coordinate the Revised Plan

Give the pharmacist the clinical context: the indication, urgency, relevant patient factors, and alternatives already considered.

Then clarify responsibilities. Who will confirm supply? Who will obtain authorization, update the prescription, or contact the patient? Unclear ownership can prolong an otherwise solvable disruption.

Pharmacy Solutions offers direct pharmacist access through its primary care provider resources for patient-specific compounding questions. Providers can discuss formulation needs and feasibility while evaluating available treatment options.

Document the agreed plan, including whether the change is temporary. Address old prescriptions or refill instructions that could cause confusion when supply returns.

Continuity of Care: Keep Patients Informed and Monitor Changes

Explain what is known, what is still being checked, and when the patient will hear back. Avoid promising a restock date that has not been confirmed.

Patients need practical instructions: which medication to use, how to use it, and whom to contact if they cannot obtain it or develop concerns. Ask them to describe the plan back to confirm understanding.

Arrange follow-up appropriate to the treatment change and clinical risk. Reassess tolerability, symptom control, and any relevant measurements.

When the original product becomes available again, review the next step with the patient. A temporary change should have a documented reassessment point.

Discuss Patient-Specific Medication Needs With Pharmacy Solutions

When treatment disruption raises a formulation question, contact Pharmacy Solutions. Its pharmacists can discuss preparation feasibility with your practice as you evaluate clinically appropriate options under applicable requirements.

Frequently Asked Questions

How should providers respond when a medication is unavailable?

Confirm the exact product, assess how much medication remains, and identify the reason for the access problem. Coordinate with the pharmacist to evaluate available options, authorize necessary changes, and communicate a clear plan to the patient.

Is a pharmacy backorder the same as an FDA-listed drug shortage?

No. A local backorder or stock problem does not automatically mean a drug is on FDA’s shortage list. Providers should verify current shortage information and product-specific availability.

Can another dosage form replace an unavailable medication?

Sometimes, but the change requires clinical review. Dosage forms may differ in absorption, delivery, dosing, and administration instructions. Providers should not assume dose-for-dose equivalence.

Can compounding address every drug shortage?

No. Compounding depends on applicable requirements, ingredient availability, preparation feasibility, and the patient’s clinical needs. An FDA shortage listing may affect certain copying restrictions, but it does not remove all other requirements.

Are all estradiol patches unavailable?

No. FDA’s September 2026 update stated that estradiol patches remained available overall despite access difficulties affecting some products and locations. Check the exact product and current local availability before making treatment decisions.

This article is intended for healthcare professional education and does not replace current prescribing information, regulatory requirements, or individualized clinical judgment. Treatment changes require appropriate supervision and monitoring. Compounded medications are not FDA-approved.